Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides

Current Cancer Drug Targets

Volumn 11, Issue 6, 2011, Pages 752-762

  Aguilar, B ^a   Amissah, F ^a   Duverna, R ^a   Lamango, N S ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Cell death; Esterase inhibitors; Methyl esterase; Molecular docking; Neuroblastoma; Polyisoprenylation; Pseudo first order kinetics; Sulfonyl fluorides

Indexed keywords

2 FARNESYLTHIOETHANESULFONYL FLUORIDE; 2 GERANYLTHIOETHANESULFONYL FLUORIDE; ANTINEOPLASTIC AGENT; BENZYLSULFONYL FLUORIDE; BENZYLTHIOETHANESULFONYL FLUORIDE; DECANYLTHIOETHANESULFONYL FLUORIDE; PHENYLMETHYLSULFONYLFLUORIDE; POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE; POLYISOPRENYLATED PROTEIN METHYL TRANSFERASE; SERINE DEHYDRATASE; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME INHIBITION; ESTERIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PROTEIN PRENYLATION;

ANIMALS; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CATALYSIS; CATALYTIC DOMAIN; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; PHENYLMETHYLSULFONYL FLUORIDE; PROTEIN METHYLTRANSFERASES; PROTEIN PRENYLATION; SUBSTRATE SPECIFICITY; SULFINIC ACIDS; SUS SCROFA;

EID: 79959959322     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796191015     Document Type: Article

References (46)

1. Oboh, O. T.; Lamango, N. S. Liver prenylated methylated protein methyl esterase is the same enzyme as Sus scrofa carboxylesterase. J. Biochem. Mol. Toxicol. 2008, 22, 51-62.
2. Lamango, N. S.; Duverna, R.; Zhang, W.; Ablordeppey, S. Y. Porcine liver carboxylesterase requires polyisoprenylation for high affinity binding to cysteinyl substrates. Open Enzym. Inhib. J. 2009, 2, 12-27.
3. Bencharit, S.; Morton, C. L.; Xue, Y.; Potter, P. M.; Redinbo, M. R. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 2003, 10, 349-356.
4. Bencharit, S.; Edwards, C. C.; Morton, C. L.; Howard-Williams, E. L.; Kuhn, P.; Potter, P. M.; Redinbo, M. R. Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J. Mol. Biol. 2006, 363, 201-214.
5. Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 2002, 102, 4639-4750.
6. Lamango, N. S. Liver prenylated methylated protein methyl esterase is an organophosphate-sensitive enzyme. J. Biochem. Mol. Toxicol. 2005, 19, 347-357.
7. Berliner, L. J.; Wong, S. S. Spin-labeled sulfonyl fluorides as active site probes of protease structure. I. Comparison of the active site environments in alpha-chymotrypsin and trypsin. J. Biol. Chem. 1974, 249, 1668-1677.
8. Lamango, N. S.; Koikov, L.; Duverna, R.; Abonyo, B. O.; Hubbard, J. B. Neurotoxicity Syndromes; Webster, L. R.; Nova Science Publishers, Inc.: New York, 2007, 37-68.
9. Seabra, M. C.; Ho, Y. K.; Anant, J. S. Deficient geranylgeranylation of Ram/Rab27 in choroideremia. J. Biol. Chem. 1995, 270, 24420-24427.
10. Pereira-Leal, J. B.; Hume, A. N.; Seabra, M. C. Prenylation of Rab GTPases: molecular mechanisms and involvement in genetic disease. FEBS Lett. 2001, 498, 197-200.
11. Seabra, M. C.; Brown, M. S.; Goldstein, J. L. Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science 1993, 259, 377-381.
12. Konstantinopoulos, P. A.; Karamouzis, M. V.; Papavassiliou, A. G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007, 6, 541-555.
13. Sebti, S. M.; Hamilton, A. D. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. Expert Opin. Investig. Drugs. 1997, 6, 1711-1714.
14. Woodward, J. K.; Coleman, R. E.; Holen, I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 2005, 16, 11-19.
15. Kitz, R.; Wilson, I. B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 1962, 237, 3245-3249.
16. Bencharit, S.; Redinbo, M. R. Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J. Mol. Biol. 2006, 363, 201-214.
17. Imai, T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab. Pharmacokinet. 2006, 21, 173-185.
18. Fleming, C. D.; Bencharit, S.; Edwards, C. C.; Hyatt, J. L., Tsurkan, L.; Bai, F.; Fraga, C.; Morton, C. L.; Howard-Williams, E. L.; Potter, P. M.; Redinbo, M. R. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J. Mol. Biol. 2005, 352, 165-177.
19. Duverna, R.; Ablordeppey, S. Y.; Lamango, N. S. Biochemical and Docking Analysis of Substrate Interactions with Polyisoprenylated Methylated Protein Methyl Esterase. Curr. Cancer Drug Targets 2010, 10, 634-648.
20. Sali, A.; Overington, J. P. Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci. 1994, 3, 1582-1596.
21. Sali, A.; Potterton, L.; Yuan, F.; van Vlijmen, H.; Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995, 23, 318-326.
22. Yanamala, N.; Tirupula, K. C.; Klein-Seetharaman, J. Preferential binding of allosteric modulators to active and inactive conformational states of metabotropic glutamate receptors. BMC Bioinformatics 2008, 9(Suppl 1), S16.
23. Perez-Sala, D. Protein isoprenylation in biology and disease: general overview and perspectives from studies with genetically engineered animals. Front. Biosci. 2007, 12, 4456-4472.
24. Seabra, M. C. New insights into the pathogenesis of choroideremia: a tale of two REPs. Ophthalmic Genet. 1996, 17, 43-46.
25. Roskoski, R., Jr. Protein prenylation: a pivotal posttranslational process. Biochem. Biophys. Res. Commun. 2003, 303, 1-7.
26. Powers, J. C.; Tanaka, T.; Harper, J. W.; Minematsu, Y.; Barker, L.; Lincoln, D.; Crumley, K. V.; Fraki, J. E.; Schechter, N. M.; Lazarus, G.G., et al. Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors. Biochemistry 1985, 24, 2048-2058.
27. Ewoldt, G. R.; Winkler, U.; Powers, J. C.; Hudig, D. Sulfonyl fluoride serine protease inhibitors inactivate RNK-16 lymphocyte granule proteases and reduce lysis by granule extracts and perforin. Mol. Immunol. 1992, 29, 713-721.
28. Seabra, M. C.; Mules, E. H.; Hume, A. N. Rab GTPases, intracellular traffic and disease. Trends Mol. Med. 2002, 8, 23-30.
29. Tolmachova, T.; Wavre-Shapton, S. T.; Barnard, A. R.; MacLaren, R. E.; Futter, C. E.; Seabra, M. C. Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia. Invest. Ophthalmol. Vis. Sci. 2010, 51, 4913-4920.
30. McCray, B. A.; Skordalakes, E.; Taylor, J. P. Disease mutations in Rab7 result in unregulated nucleotide exchange and inappropriate activation. Hum. Mol. Genet. 2010, 19, 1033-1047.
31. Bredel, M.; Pollack, I. F.; Freund, J. M.; Hamilton, A. D.; Sebti, S. M. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery 1998, 43, 124-131; discussion 131-132.
32. Caraglia, M.; Budillon, A.; Tagliaferri, P.; Marra, M.; Abbruzzese, A.; Caponigro, F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr. Drug Targets. 2005, 6, 301-323.
33. Dinsmore, C. J.; Bell, I. M. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity. Curr. Top. Med. Chem. 2003, 3, 1075-1093.
34. Ghobrial, I. M.; Adjei, A. A. Inhibitors of the ras oncogene as therapeutic targets. Hematol. Oncol. Clin. North Am. 2002, 16, 1065-1088.
35. Sebti, S. M. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 2005, 7, 297-300.
36. Read, D. J.; Li, Y.; Chao, M. V.; Cavanagh, J. B.; Glynn, P. Organophosphates induce distal axonal damage, but not brain oedema, by inactivating neuropathy target esterase. Toxicol. Appl. Pharmacol. 2010, 245, 108-115.
37. Arima, H.; Sobue, K.; So, M.; Morishima, T.; Ando, H.; Katsuya, H. Transient and reversible parkinsonism after acute organophosphate poisoning. J Toxicol Clin Toxicol. 2003, 41, 67-70.
38. Ascherio, A.; Chen, H.; Weisskopf, M. G.; O'Reilly, E.; McCullough, M. L.; Calle, E. E.; Schwarzschild, M. A.; Thun, M. J. Pesticide exposure and risk for Parkinson's disease. Ann. Neurol. 2006, 60, 197-203.
39. Bhatt, M. H.; Elias, M. A.; Mankodi, A. K. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology 1999, 52, 1467-1471.
40. Davis, K. L.; Yesavage, J. A.; Berger, P. A. Single case study. Possible organophosphate-induced parkinsonism. J. Nerv. Ment. Dis. 1978, 166, 222-225.
41. Glynn, P. Neuropathy target esterase (NTE): molecular characterisation and cellular localisation. Arch Toxicol. Suppl. 1997, 19, 325-329.
42. Glynn, P.; Read, D. J.; Lush, M. J.; Li, Y.; Atkins, J. Molecular cloning of neuropathy target esterase (NTE). Chem. Biol. Interact. 1999, 119-120, 513-517.
43. Glynn, P. Neural development and neurodegeneration: two faces of neuropathy target esterase. Prog. Neurobiol. 2000, 61, 61-74.
44. Johnson, M. K.; Glynn, P. Neuropathy target esterase (NTE) and organophosphorus-induced delayed polyneuropathy (OPIDP): recent advances. Toxicol. Lett. 1995, 82-83, 459-463.
45. Glynn, P. A mechanism for organophosphate-induced delayed neuropathy. Toxicol. Lett. 2006, 162, 94-97.
46. Glynn, P. Axonal degeneration and neuropathy target esterase. Arh Hig. Rada Toksikol. 2007, 58, 355-358.